Biotech · Private company
ImmunoGen, Inc.
Track this companyFree. Adds ImmunoGen, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials102 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- Mirvetuximab SoravtansinePhase 3 · Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Pegylated liposomal doxorubicinPhase 3 · Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- TopotecanPhase 3 · Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- IMGC936Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- IMGN779Phase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Mirvetuximab soravtansinePhase 1 · TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- First-in-Human Study of IMGC936 in Participants With Advanced Solid TumorsPHASE1_PHASE2 · COMPLETED · started Oct 29, 2020ClinicalTrials.gov NCT04622774 · fetched Nov 12, 2026
- A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionPHASE3 · COMPLETED · started Jul 23, 2020ClinicalTrials.gov NCT04296890 · fetched Nov 12, 2026
- Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial CancerPHASE2 · RECRUITING · started Jul 15, 2020ClinicalTrials.gov NCT03832361 · fetched Nov 12, 2026
- A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 2, 2020ClinicalTrials.gov NCT03835819 · fetched Nov 12, 2026
- Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerPHASE1 · COMPLETED · started Jul 12, 2018ClinicalTrials.gov NCT03552471 · fetched Nov 12, 2026
- Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid TumorsPHASE1 · COMPLETED · started May 26, 2017ClinicalTrials.gov NCT03102320 · fetched Nov 12, 2026
- Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerPHASE1_PHASE2 · COMPLETED · started Mar 2, 2016ClinicalTrials.gov NCT02606305 · fetched Nov 12, 2026
- A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube CancerPHASE3 · COMPLETED · started Mar 2, 2016ClinicalTrials.gov NCT02631876 · fetched Nov 12, 2026
- Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid LeukemiaPHASE1 · COMPLETED · started Mar 1, 2016ClinicalTrials.gov NCT02674763 · fetched Nov 12, 2026
- First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid TumorsPHASE1 · COMPLETED · started Jun 28, 2012ClinicalTrials.gov NCT01609556 · fetched Nov 12, 2026